Although the outcome for Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) with conventional chemotherapy is poor, the outcome after a siblingmatched allogeneic bone marrow transplantation (BMT) seems to be significantly better. The surprising success of allogeneic BMT may be because of disease response to high-dose chemotherapy combined with a graft-versusleukemia effect. However, less than 30% of patients have a matched related donor available, and some of them will be too old/not fit for conventional BMT. While young patients who do not have a matched related donor should be considered for matched unrelated donor (MUD) transplant, older patients may be treated with autologous stem cell transplantation (ASCT) or rarely considered for a low-intensity MUD transplant. The efficacy of autologous BMT compared with chemotherapy is still debatable, although the new tyrosine kinase inhibitor Imatinib may be used for pretransplant purging/posttransplant therapy, aiming to improve autologous and allogeneic BMT results. The advantage of low-intensity sib/MUD allograft compared with chemotherapy is not proven either and is currently under investigation. However, if shown to be curative, low-intensity allograft may significantly improve the outcome of older Ph+ ALL patients, who are not eligible for conventional allograft. Bone Marrow Transplantation (2003Transplantation ( ) 31, 623-632. doi:10.1038 Keywords: autologous; allogeneic bone marrow transplantation; Ph+ ALL The Philadelphia chromosome (Ph) represents the most common cytogenetic abnormality in adult acute lymphoblastic leukemia (ALL). It occurs in fewer than 5% of ALL cases in children, but in around 20-30% of cases in adults, with an increasing incidence with age.
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Although the outcome for Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) with conventional chemotherapy is poor, the outcome after a siblingmatched allogeneic bone marrow transplantation (BMT) seems to be significantly better. The surprising success of allogeneic BMT may be because of disease response to high-dose chemotherapy combined with a graft-versusleukemia effect. However, less than 30% of patients have a matched related donor available, and some of them will be too old/not fit for conventional BMT. While young patients who do not have a matched related donor should be considered for matched unrelated donor (MUD) transplant, older patients may be treated with autologous stem cell transplantation (ASCT) or rarely considered for a low-intensity MUD transplant. The efficacy of autologous BMT compared with chemotherapy is still debatable, although the new tyrosine kinase inhibitor Imatinib may be used for pretransplant purging/posttransplant therapy, aiming to improve autologous and allogeneic BMT results. The advantage of low-intensity sib/MUD allograft compared with chemotherapy is not proven either and is currently under investigation. However, if shown to be curative, low-intensity allograft may significantly improve the outcome of older Ph+ ALL patients, who are not eligible for conventional allograft. Bone Marrow Transplantation (2003) 31, 623-632. doi:10.1038/sj.bmt.1703899 Keywords: autologous; allogeneic bone marrow transplantation; Ph+ ALL The Philadelphia chromosome (Ph) represents the most common cytogenetic abnormality in adult acute lymphoblastic leukemia (ALL). It occurs in fewer than 5% of ALL cases in children, but in around 20-30% of cases in adults, with an increasing incidence with age. 1, 2 Reciprocal translocation between chromosomes 9 and 22 creates the Ph chromosome, producing a proto-oncogene responsible for the malignant transformation. [3] [4] [5] Ph+ ALL accounts for the majority of adult ALL patients who have poor-risk cytogenetics. However, other cytogenetic abnormalities are known to be associated with poor prognosis, such as t(4:11), t(1:19), À7, and +8 (Table 1) .
Although more than 60% of patients with Ph+ ALL succeed in achieving complete remission, most of them will relapse and fewer than 10-20% will remain alive 5 years after diagnosis. 1, [6] [7] [8] [9] Even more aggressive regimens like hyper-CVAD are not confirmed as improving overall survival (OS). 6 It seems therefore that proceeding to an early bone marrow transplant (BMT) is the most likely route to achieve cure in adult Ph+ ALL patients. [9] [10] [11] The best treatment for patients who are not eligible for allogeneic BMT (for example, patients who are not young or fit enough), or do not have a matched related donor, is still debated. Autologous BMT with or without stem cell purging can be an option, although results are still disappointing. Younger patients with good performance status might be considered for matched unrelated donor (MUD) BMT. However, transplant-related mortality (TRM) is still very high.
(A summary of the advances in diagnosis and treatment in ALL is presented in Table 2 ).
Stem cell transplant

Allogeneic stem cell transplant
The poor outcome with conventional chemotherapy makes allogeneic BMT an attractive option for patients with Ph+ ALL. Forman et al initially reported the outcome of allogeneic BMT in 10 adult patients with Ph+ ALL (four in CR1, six with active disease). Four patients died of transplant-related complications, while six patients survived the transplant and remained in complete remission (CR) (median follow-up; 19 months). 12 Barrett et al 13 analyzed retrospectively the outcome of allogeneic SCT in 67 Ph+ ALL patients, aged 5-49 years (median age: 28 years). Out of 67 transplant recipients 21 (31%) were still in continuous CR, X2 years after transplant. However, TRM and morbidity were both high, characterized by a high incidence of grade 2-4 acute/chronic graft-versus-host disease (GVHD) (each occurring in approximately one-third of the patients) and interstitial pnuemonitis (30%). Surprisingly, there were no significant differences in TRM, disease-free survival (DFS) and relapse rate between patients who had been transplanted in first or later CR. However, 2-year DFS was much lower in patients who had never achieved CR before transplant (DFS ¼ 25%), reflecting the higher progression rate observed in this group (Table 3) . Better results were reported in more recent studies (Table 3) . [9] [10] [11] 14, 15 Snyder et al 10 have recently reported a 65% DFS rate (15/23) at 3 years post-transplant. The estimated relapse rate during that period was 12%. The relatively low relapse rate might be because of graft-versus-leukemia effect. However, 7/23 (30%) of the patients died from transplant-related causes. 10 Chao et al 15 suggested an advantage for matched related donor transplant carried out at first CR, with a DFS of 46% (2-year confidence interval (CE) 725%), compared with 28% DFS in patients transplanted after having a relapse.
Although it appears that allogeneic SCT has succeeded in improving the outcome of Ph+ ALL patients, the OS is still unsatisfactory. There are three major reasons for this, including:
(1) High toxicity of transplant. 9, 10, 16 (Table 3) . (2) Referral of patients with advanced disease to transplant (CR2 or later) rather than early transplant in first CR (Table 4) . 16 (3) Long interval between diagnosis and transplant, especially in patients who do not have matched related donor and need a search for an unrelated one. 16 A shorter interval from diagnosis to transplant has been associated with lower risk of TRM, unrelated to disease status at transplantation. 16 (1) Toxicity of transplant is at least partially related to aggressive conditioning regimens used pretransplant, based on total body irradiation (TBI) combined with high-dose cyclophosphamide/etoposide or busulfan. 9, 10 There might be a tendency for reduction in treatment-related mortality over time, most probably reflecting the improvement in supportive care. 9, 10 (The MRC UKALL12/ECOG trial observed a significant reduction in TRM from 53% between 1993 and 1996, to less than 30% between 1997 and 2000 in Ph+ ALL patients allografted in CR1.) 9 (2) Most of the studies confirm the advantage of having the transplant in first CR compared to later. (Table 4) . 11, [15] [16] [17] [18] Based on these data, it seems attractive to try and transplant these patients in first CR. Arico et al 11 have analyzed the outcome of children with Ph+ ALL treated 19 All patients who entered into remission and had a matched related/unrelated donor were assigned to allo-SCT, whereas those without a donor had an autologous SCT. Pre-and post-transplant analysis for minimal residual disease (detected by specific reverse transcriptase-polymerase chain reaction (RT-PCR) for Bcr/Abl) was carried out in all patients. The existence of a donor and absence of minimal residual disease pretransplantation were both associated with a longer DFS (Po0.001 and ¼ 0.01, respectively) and OS (P ¼ 0.02 and 0.01, respectively) ( Table 3) . 19 The most recent and biggest prospective randomized study ever carried out in adult ALL, the ongoing UKALL12/ECOG 2993, reported the outcome in 167 Ph+ ALL patients who were treated between 1993 and 2000, according to the UKALL12/ECOG E2993 protocol (Table 3) . 9 In all, 49 patients had a matched related donor transplant in first CR, 23 had a MUD transplant, seven had autologous BMT (ABMT) and 88 were treated with chemotherapy. The actuarial 5-year relapse risk for patients who had an allogeneic transplant (related or unrelated donor) was 32%, compared with 81% for patients who were treated with maintenance chemotherapy or autologous SCT (Po0.0001). As expected, 5-year EFS and OS were higher in the allogeneic recipients, and approached 36 and 42%, respectively, compared with 17 and 19 in nonallogeneic transplanted patients ( Figure 1 ) (Table 3) . It therefore appears reasonable to refer patients with Ph+ ALL to allogeneic transplant in first CR. However, most of the patients eligible for transplant (good performance status, age below 50-60 years) do not have a MUD. Should these patients be referred for MUD?
MUD transplantation
Arico et al 11 confirmed a significant benefit for MR-SCT in children with Ph+ ALL. However, no other type of transplant, including MUD transplant, had a better outcome than chemotherapy. Nine out of 21 (43%) children who had a MUD transplant died of transplantrelated complications (no details about GVHD prophylaxis or GVHD-related mortality were given). However, only 4/ 21 relapsed (19%), confirming the superior antileukemic effect provided by the allograft (Table 5) . 11 Marks et al 20 tried to clarify the role of MUD transplant in patients with Ph+ ALL (Table 5 ). In all, 15 children and adolescents, nine in CR1, five with later CR and one with active leukemia, had T-cell-depleted MUD-BMT (T-cell depletion was performed with Campath/CD34 selection). In all, 11 patients had fully matched donors, while four had one or two alleles mismatched. Seven patients (47%) survived at a median follow-up of 21 months, six of them remained in CR. The two-year overall and disease-free survivals were 44713% and 37713%, respectively. The incidence of A-GVHD and C-GVHD was low, but the relapse rate was high (40%). None of the four patients who had a mismatched donor survived, compared with seven out of eleven (63%) patients who had a fully matched donor (Po0.05). There was a tendency for better survival in children transplanted in first CR compared with a later CR (5/9 compared with 2/6). However, it was statistically insignificant, most probably related to the small number of patients in each of these subgroups. 20 The lower TRM observed in this study 20 compared with Arico's study 11 might reflect the use of T-cell depleted marrows. However, the median time to transplant was shorter as well, 6 months compared with 21 months. The advantage of T-cell depletion might be reversed by the high relapse rate in CR1, 16 in CR2 or CR3 and 47 with active leukemia. Two-year OS was 40% for patients in CR1, 17% in CR2/3 and 5% in patients transplanted with disease. Multivariable analysis showed that CR1, shorter interval from diagnosis to transplantation, DRB1 match, negative cytomegalovirus (CMV) serology of patient and donor and presence of a Ph chromosome were independently associated with better DFS. TRM in patients transplanted in CR1 was high and approached 54%. However, a shorter interval from diagnosis to transplantation, good performance status, negative CMV DRB1-match and higher stem cell dose were all associated with reduced TRM. 16 Goldstone et al, 9 in their ongoing prospective randomized study, showed a significantly reduced relapse risk with MUD, compared with chemotherapy/ASCT (32 vs 81% at 5 years post-transplant, P ¼ 0.0005, Figure 2 Table 5 .)
The relatively good results of allogeneic BMT (matched related and MUD) compared with conventional chemotherapy are because of the existence of graft-versusleukemia (GVL) effect, 21, 22 in addition to the myeloablation obtained with high-dose radio-chemotherapy. Ph+ ALL patients should therefore be considered for allogeneic stem cell transplantation in first CR. However, ways to reduce TRM are currently being investigated.
Autologous stem cell transplantation
Based on the poor prognosis with conventional chemoradiotherapy compared with allogeneic SCT, experts agree now that Ph+ ALL patients should have an allogeneic SCT in first remission. However, the majority of the patients are too old for T-replete allogeneic SCT or do not have an HLA-matched sibling as a donor. These patients can therefore be considered for MVD SCT (if young and fit enough), or alternatively for autologous SCT.
Several studies evaluated the role of autologous SCT in Ph+ ALL patients. 11, 23, 24 Arico et al 11 found no advantage for autologous BMT in first CR for children with Ph+ ALL compared with conventional chemotherapy (RR for relapse ¼ 1.1). Only 6/ 25 (24%) children who had autologous SCT in first CR survived the transplant and continued to be in CR (with no further complication like a secondary neoplasm) 2 years after transplant. 11 Similar grim results were reported in adult Ph+ ALL patients, with a relapse rate of 70-80% post-autograft. 9, 24 The significantly higher relapse rate after ABMT compared with allogeneic transplant is likely to be because of the absence of graft-versus-tumour effect, but may sometimes also reflect re-infusion of residual malignant cells with the autologous stem cells. 25 It has already been demonstrated that most if not all patients with Ph+ ALL who are considered as being in CR still have minimal residual disease (MRD), proven by cytogenetic or polymerase chain reaction (PCR) for Bcr-Abl. 23, 26 Furthermore, reappearance of a positive PCR for BcrAbl after the patient has already achieved molecular remission predicts clinical relapse in a few months in at least 40% of the patients. 27, 28 Therefore, the role of pretransplant stem cell purging has been investigated, aiming to prolong DFS and reduce relapse rate by sending the patient to transplant with the minimum disease as possible.
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Pretransplant stem cell purging Pretransplant stem cell purging can be carried out by eliminating the tumor cells, using antibodies directed against antigens expressed by Ph+ ALL cells (CD10, CD19, CD20), or by selecting out only the stem cells (cells that express CD34 antigen).
Morishima et al 29 performed autotransplant in four Ph+ALL patients in first CR, using immunologically purged bone marrows. Ex vivo, pretransplant purging was carried out with combinations of monoclonal antibodies directed against antigens expressed by Ph+ ALL cells. Marrow was analyzed for minimal residual disease after having been purged, using PCR analysis for Bcr-Abl. None of the bone marrows showed evidence of residual disease. At the time of publication, three out of four patients remained in CR, 77, 29 and 26 months post-transplant. BMT in Ph+ ALL patients I Avivi and AH Goldstone
New approaches
Minimal residual disease
Studies to detect MRD post-therapy, aiming to identify patients at higher risk for relapse, are currently being pursued. The main methods being used are flow cytometry, based on detection of the phenotypic markers expressed by leukemic cells, 30, 31 and PCR for VH-(DH)-JH/TCR rearrangement. [32] [33] [34] MRD status is now established as an independent risk factor, in childhood ALL. Most studies showed molecular remission ( ¼ PCR negativity) to be associated with longterm DFS, while reconversion to MRD positivity is associated with impending clinical relapse. 32, 33 MRD positivity was found to be an independent risk factor at least as powerful as age/initial WBC count and karyotype. 32, 33 Other studies claimed MRD to be less reliable in predicting relapse in adult ALL patients. 35, 36 However, a recent study, reported by Mortuza et al, 34 confirmed a positive MRD test to be highly predictive for impending relapse in adult Ph-ALL patients. MRD positivity, detected by a patient's specific clonal VH-(DH)-JH rearrangement, was associated with increased relapse rates (Po0.05), most noticeable at 3 and 5 months postinduction and beyond. MRD status after allogeneic BMT rather than before, appears to predict transplant outcome. 34 MRD positivity for Bcr-Abl, observed in Ph+ ALL patients, seems to have a similar clinical significance. Radich et al 27 reported a significantly increased RR in patients who had positive PCR for Bcr-Abl post-transplant (RR ¼ 43%), compared with patients with no positive tests (15%) (most patients reported in this study had allo-SCT). 27 However, data regarding the significance of postallograft MRD are still limited and further studies are needed. The MRC/ECOG group is planning to perform MRD tests pre/post-transplant in all transplanted patients.
It appears that MRD analysis is going to affect our clinical decisions. Although it seems that PhÀ ALL patients who achieve molecular remission may do well without transplant 34 (although this needs further evaluation), it might not be the case with Ph+ patients, whose relapse risk without transplant is extremely high.
New drugs
Tyrosine kinase (Tk) inhibitors Protein kinases are proteins participating in signal transduction pathways involved in cell growth, differentiation and apoptosis. Translocation between chromosomes 9 and 22 creates the Ph chromosome, typical of chronic myeloid leukemia and Ph+ ALL. The molecular consequence of this translocation is the replacement of the first axon of c-Abl with a sequence from the Bcr gene, resulting in a Bcr-Abl fusion gene, the protein product of which shows an enhanced protein kinase activity. [3] [4] [5] The fusion oncoprotein in CML is a 210 kda protein, whereas patients with Ph+ ALL are more likely to have a different 190 kda, oncoprotein produced by a different breakpoint in the Bcr gene. 1, 37, 38 Expression of p210 Bcr-Abl has been shown to induce CML in mice, confirming this oncoprotein to be essential for the development of the malignant transformation. 39 Its transforming function is dependent on the protein kinase activity, 40 which made this TK an attractive target for therapeutic inhibition.
Imatinib (STI571), an Abl-specific TK inhibitor able to affect p-210 Bcr-Abl and p-190 Bcr-Abl similarly, has already been shown to be effective in CML patients. A major cytogenetic response and a complete hematological response were achieved in 60 and 95% of CML patients (chronic phase) who received Imatinib after failure to respond to interferon -a. 41 Phase 1 and 2 studies confirmed imatinib to be effective in patients with Ph+ ALL or CML in lymphoid blast crisis, with an overall response rate of 70-82%, including 25-55% CRs. [42] [43] [44] However, responses did not persist for a long period. [42] [43] [44] Therefore, it seems that Imatinib might be used for in vivo purging followed by ASCT, or as an adjuvant therapy post-transplantation, aiming to improve the outcome of patients who are not eligible for allogeneic SCT. Mopping up with Imatinib might be considered in patients postallogeneic SCT as well, or as a treatment in patients who relapsed post-transplantation. However, the role of all these treatments has to be proven in further studies and compared with the activity and toxicity of donor lymphocyte infusion for patients with molecular/clinical relapse post-allogeneic SCT.
According to the updated protocol of the ongoing ECOG2993/UKALL12, all patients with Ph+ ALL who achieve CR or have a significant response to induction chemotherapy will be treated with Imatinib for 4 weeks (study protocol- Figure 3 ). Patients with a potential donor will have allogeneic stem cell transplantation, followed by STI. Patients with no matched donor, or those who are not eligible for allogeneic SCT, will be treated with ASCT followed by Imatinib, until relapse. Morphological, cytogenetics and molecular response will be regularly assessed in all patients recruited to this protocol during treatment.
There are new signal transduction inhibitors being developed, including B43-Genistein, a CD19-directed TK inhibitor able to induce apoptosis of CD19 positive cells, and inhibitors affecting TK receptors involved in angiogenesis, such as FLK-1/KDR. 46 The efficacy of SU5416, an inhibitor of FLK-1/KDR, is currently being investigated, and results of these studies are awaited.
Growth factor receptor-bound protein-2 (Grb2) is a key downstream protein in the RAS signal transduction pathway, initiated by various TKs, including Bcr-Abl. Activation of Bcr-Abl, causes stimulation of RAS, mediated by Grb-2. 47 Inhibition of Grb-2 can selectively inhibit the growth of Bcl-Abl-positive cells. Further studies are needed to prove if Grb-2 downregulation can provide a therapeutic strategy for Ph+ ALL patients.
Other new drugs in ALL Antisense oligonucleotides Antisense oligonucleotides are short DNA sequences able to bind target RNA sequences within the cell and thereby prevent translation of the RNA message into functional proteins. Bcr-Abl antisense oligonucleotides are able to decrease the proliferation rate of Ph+ CML cells. 48 A similar approach might be taken for Ph+ ALL, although it has to be proven as having a clinical efficacy.
Bcl-2 antisense oligonucleotides, aiming to reduce the over expression of the antiapoptotic protein Bcl-2, have been suggested to be effective in those ALL patients who have an increased Bcl-2 expression or high ratio of Bcl-2/ Bax. 49, 50 Furthermore, modulation of Bcl-2 followed by increased apoptosis of ALL cells has been observed with Bryostatin, a macrocyclic lactone isolated from the marine bryozoan Bugula neritina.
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Proteasome inhibitor PS-341
The proteasomes are multisubunit enzyme complexes that reside in the cytoplasm and nucleus of eucaryotic cells and are essential for proteolytic degradation of most intracellular proteins. The proteasomes are able to modulate various kinds of enzymes, including proteins involved in cell cycle regulation, cell survival and gene expression. Inhibiting the proteosome pathway might modulate the expression of proteins involved in tumorigenesis. 51, 52 PS-341, a potent selective inhibitor of the proteasome, is currently being investigated in solid and hematological malignancies, including myeloma and ALL patients. Encouraging results have been reported recently in myeloma patients treated with PS341. 53 A total of 85% of patients with relapsed/refractory myeloma showed response/stabilized disease after two courses of PS341, including few CRs.
Results of the ongoing study investigating the effect of PS341 in refractory/relapsed ALL patients are awaited All these novel drugs might change our future view on ALL treatment. However, none of them seems to be an alternative therapy for allogeneic SCT, which is still the only proven curative therapy for patients with Ph+ ALL.
Immunotherapy
Different immunomodulators, including interleukin-2 (IL2), have been suggested to induce an immunological response, similar to the graft-versus-leukemia effect. Current studies have failed to show any advantage of adding IL2 to conventional adult ALL therapy. 54, 55 a-Interferon (given in addition to chemotherapy) was suggested to possibly prolong survival in Ph+ ALL patients who achieved CR with conventional chemotherapy. 56 Theoretically, it might be even more effective in patients who have been autografted and are expected to have a smaller amount of minimal residual disease.
Monoclonal antibodies (MoABs), directed against surface antigens, expressed by the tumor cells, are being investigated. [57] [58] [59] [60] CD20 antigen, detected in 55% of Ph+ ALL patients, has been suggested to be an attractive target for immunotherapy. Pretransplant in vivo purging with anti-CD20 MoABs (rituximab) has been recently reported to be effective, with an achievement of molecular remission in Ph+ ALL patients. 57 However, the long-term effect of this treatment is not proven.
Alemtuzumab (Campath-1-H) has also been reported to be effective in ALL patients, achieving CR in three out of five ALL patients (one with Ph+ ALL) who failed to respond to conventional chemotherapy. 59 It has also been suggested to be an effective treatment for pretransplant in vivo purging. 60 However, the numbers of patients are too small and follow-up is too short to assess the long-term effect of this treatment.
Anti-CD33 conjugated to calicheamicin, most commonly known as a potential treatment for acute myeloid leukemia (AML), is currently being investigated as a treatment for ALL, as a high proportion of Ph+ ALL patients express CD33 on their lymphoblasts. 8, 61 The significance of all these MoABs has yet to be proven before their use can be widely recommended and combined with current transplant protocols.
New kinds of allogeneic transplantation
Other new emerging techniques for allogeneic BMT, including haploidentical and low-intensity bone marrow transplant, are still not of proven value for ALL patients.
Low-intensity allogeneic BMT
Low-intensity SCT is being increasingly used for different kinds of hematological malignancies, aiming to exploit the curative potential of allo-SCT by inducing graft-versustumour effect without the morbidity and mortality associated with conventional transplantation.
Experience with a low-intensity allo-SCT in ALL patients is still very limited and data are scanty. Martino et al 31 evaluated the outcome of 27 adult ALL patients (11/ 27 had Ph+ ALL), treated with a low-intensity allograft. All patients participated in multinational prospective studies and received matched /mismatched related allograft or MUD transplant. The majority of the patients were transplanted with advanced disease (n ¼ 11 in CR2/3; 12 with chemorefractory disease). The TRM, progression of disease and OS at 2-year post-transplant were 23 and 30%, respectively. The incidence of grades II-IV acute GvHD was 48%, and 13 of 18 evaluable patients (72%) developed chronic GvHD. 31 However, the number of patients included in this study is small, and follow-up is still limited. Although GVL may be operated in some patients, its ability to overcome residual disease left after reduced intensity conditioning regimen is still unclear.
Larger studies with longer follow-ups are needed to confirm the potential advantage of low-intensity SCT in ALL patients.
Haploidentical SCT is a new approach, which offers a potential donor to most of the patients who lack a matched sibling donor. The experience with haploidentical SCT in ALL patients is still limited.
Aversa et al 62 have recently reported the outcome in 40 ALL (9/40 in CR1) patients, treated with haploidentical SCT. At the time of publication (median follow-up of 2 years), 17/40 patients have relapsed/progressed and 8/40 were in continuing CR. Four of the nine ALL patients transplanted in first CR remained in remission. The relatively high relapse rate compared with that observed in AML patients treated with the same transplant protocol is at least partially because of the lack of donor NK cell alloreactivity against ALL cells.
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Donor NK alloreactivity seems to be a unique phenomenon of mismatched transplants, as the donor's 'NK cell killer inhibitory receptors' (KIR) do not recognize the MHC allotype of the recipient as self. The exhibition of such alloreactivity is dependent on the recognition of a particular epitope shared by specific HLA allotypes. 63 Relapse rate post-mismatched transplantation appears to be inversely correlated with the donor's ability to present antirecipient NK cell alloreactivity. The lack of donor NK cell alloreactivity against ALL cells might explain the relatively high relapse rate observed so far.
However, a larger number of patients, a longer follow-up and more data regarding patients transplanted in CR1 are needed. The ongoing UKALL-12/ECOG2993 protocol will allow Ph+ ALL patients with no matched sibling donor to be considered for haploidentical SCT in CR1 (Figure 3 ).
Donor lymphocyte infusion
Is post-transplant donor lymphocyte infusion sometimes helpful? Several reports have shown a strong association between the existence of post-transplant GVHD and a lower relapse risk 22, 64 Therefore, donor lymphocyte infusion has been suggested to augment this antileukemic effect even further. 21, 65 Although response following DLI in patients with relapsed ALL is considered to be disappointing, [66] [67] [68] some recent publications suggest DLI to be effective in some of the patients. 21, 65 Schaap et al 21 reported a significant reduction in relapse rate in ALL patients who had an allogeneic BMT followed by pre-emptive DLI therapy. Although this study evaluated a heterogeneous group of ALL patients and not only those with Ph+ ALL, the role of pre-emptive DLI should be particularly considered in this group of patients, whose outcome post-allo-BMT is still not as good as that of PhÀ ALL patients. 9, 69 DLI might be indicated in patients with morphological or even molecular relapse after allogeneic BMT. Donor-derived CD8+ T cells, specifically targeted against the tumor cells, have been recently developed at the City of Hope hospital. Preclinical trial with CD8+ T cells specifically targeting CD20-positive cells showed a specific cytolytic activity against CD20 positive cells. 70 Similar clones, targeted against CD19, are under development. 71 Conclusion (Table 6) Compared with the grim prognosis of Ph+ ALL with conventional chemotherapy, reflected by o10-20% survival rate, the outcome with matched related allogeneic BMT is significantly better, with 40-50% chance of being cured. Patients with Ph+ ALL who have a matched related donor and are young and fit enough should be transplanted in first CR. Young patients without a matched related donor should be considered for MUD BMT, although the treatment-related mortality is still very high.
Results with an autologous BMT are still very disappointing with no proven advantage comparing autograft in CR1 to conventional maintenance chemotherapy. However, pretransplant purging of peripheral stem cell harvest using Imatinib might be more helpful in obtaining prolonged remissions in autologous transplant patients. 
